View Author
patient cancer breast tumor breast cancer level mutation tamoxifen status response therapy protein analysis factor treatment study bcar 1 disease table value model receptor prognostic group methylation adjuvant bcar 1 levels breast cancer patients tamoxifen treatment month tamoxifen therapy multivariate menopausal status tissue pai -2 result prognosis survival expression tp 53 adam -9 plasminogen tp 53 mutation chemotherapy association sample first-line prognostic value nodal status base model assay activator menopausal urokinase-type plasminogen activator 0.0001 adjuvant therapy breast tumors ratio tp 53 gene analyses multivariate analysis system variable dna methylation status function nodal urokinase relapse -11 adam -11 node-positive patients follow-up postmenopausal progression-free survival psat 1 upa system inhibitor dna methylation resistance estrogen
7 Most Recent Publications
|
CHEK2 1100delC and male breast cancer in the Netherlands
(Article)
Wasielewski, M. Bakker, M.A. den Ouweland, A.M.W. van den Meijer van Gelder, M.E. Portengen, H. Klijn, J.G.M. Meijers-Heijboer, E.J. Foekens, J.A. Schutte, M. |
2008-01-01
|
|
How ADAM-9 and ADAM-11 differentially from estrogen receptor predict response to tamoxifen treatment in patients with recurrent breast cancer: a retrospective study.
(Article)
Sieuwerts, A.M. Meijer van Gelder, M.E. Timmermans, M.A. Trapman, A.M. Garcia, R.R. Arnold, M. Goedheer, A.J. Portengen, H. Klijn, J.G.M. Foekens, J.A. |
2005-10-15
|
|
Association of DNA methylation of phosphoserine aminotransferase with response to endocrine therapy in patients with recurrent breast cancer.
(Article)
Martens, J.W.M. Nimmrich, I. Meijer van Gelder, M.E. Piepenbrock, C. Olek, A. Hofler, H. Kiechle, M. Klijn, J.G.M. Schmitt, M. Maier, S. Foekens, J.A. Koenig, T. Look, M.P. Harbeck, N. Model, F. Kluth, A. Bolt-de Vries, J. Sieuwerts, A.M. Portengen, H. |
2005-05-15
|
|
The prognostic value of BCAR1 in patients with primary breast cancer.
(Article)
Dorssers, L.C.J. Grebenchtchikov, N. Tienoven, D.T. van Geurts-Moespot, A. Span, P.N. Foekens, J.A. Sweep, F.C. Brinkman, A. Look, M.P. Broekhoven, S.P. van Jong, D. de Peters, H.A. Portengen, H. Meijer van Gelder, M.E. Klijn, J.G.M. |
2004-09-15
|
|
Combined vascular endothelial growth factor and TP53 status predicts poor response to tamoxifen therapy in estrogen receptor-positive advanced breast cancer
(Article)
Berns, P.M.J.J. Portengen, H. Vossen, R. Peters, H. Geurts-Moespot, A. Staveren, I.L. van Foekens, J.A. Meijer van Gelder, M.E. Sweep, F.C. Bakker, B. Klijn, J.G.M. Look, M.P. Grebenchtchikov, N. |
2003-01-01
|
|
The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients
(Article)
Foekens, J.A. Henzen-Logmans, S.C. Janicke, F. Meijer van Gelder, M.E. Klijn, J.G.M. Putten, W.L.J. van Peters, H.A. Look, M.P. Portengen, H. Schmitt, M. Kramer, M.D. Brunner, N. |
2000-01-01
|
|
Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer
(Article)
Berns, P.M.J.J. Cornelisse, C.J. Putten, W.L.J. van Inganas, M. Portengen, H. Meijer van Gelder, M.E. Claassen, C.J. Foekens, J.A. Vossen, R. Look, M.P. Klijn, J.G.M. Devilee, P. Henzen-Logmans, S.C. Staveren, I.L. van Bakker, B. |
2000-01-01
|
